XRCC4

Across TCGA pan-cancer cohorts, XRCC4 mass-spec protein differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of XRCC4’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where XRCC4 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types XRCC4 is over-expressed in tumor.

HNSC, COAD, and LUAD are the cancer types where XRCC4 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in XRCC4 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	IV	+0.460	<.001	11	view →
COAD	Female	III,IV	+0.481	<.001	10	view →
LUAD	Female	All	+0.441	<.001	9	view →
LSCC	Male	II,III,IV	+0.350	<.001	8	view →
CCRCC	All	II,III,IV	+0.120	<.001	6	view →
PDAC	All	All	+0.210	<.001	4	view →
OV	All	All	+0.356	.005	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

XRCC4–HNSC

Open the HNSC breakdown →